NovoTTF-200A Together With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed GBM

  • End date
    Dec 1, 2021
  • participants needed
  • sponsor
    Tel-Aviv Sourasky Medical Center
Updated on 22 January 2021


Study Objectives: To compare the efficacy and safety outcome of newly diagnosed GBM patients treated with NovoTTF-200A concomitant to RT and TMZ to those treated with RT and TMZ alone Study Design: Prospective, randomized, open label, standard of care control Study Hypothesis: The hypothesis of this study is that addition of NovoTTF-200A treatment to RT and TMZ will significantly increase progression free survival of newly diagnosed GBM patients compared to patients treated with RT and TMZ alone Sample Size: 60 patients with newly diagnosed GBM Study Population: Patients with tissue based diagnosis of GBM, above 18 years of age, of both genders after surgery or biopsy amenable for radiation therapy (RT) with concomitant TMZ (Stupp protocol1)

Primary endpoint:

Rate of progression-free survival at 12 months (PFS12)

Secondary endpoints:

  • Overall survival (OS)
  • Progression-free survival (PFS)
  • Progression free survival at 6 months (PFS6)
  • 1 and 2-year survival rates
  • Overall radiological response (ORR, per RANO criteria)
  • Safety (adverse events severity and frequency)


Glioblastoma (GBM), a malignant form of astrocytoma, is the most common primary intracranial neoplasm in adults2. The incidence of GBM increases steadily above 45 years of age with a prevalence of approximately 7500 cases in the USA. Despite numerous attempts to improve the outcome of patients with GBM, the 3-year survival of patients treated with maximal surgical resection when feasible, 60 Gy radiotherapy (RT) together with concomitant temozolomide (TMZ) (RT/TMZ), followed by maintenance (adjuvant) TMZ for 6 months was only 6% with median survival of 14.6 months1. In a prospective phase 3 trial, the addition of TTFields (200 kHz) to maintenance temozolomide increased the median overall survival of patients enrolled in the study following RT/TMZ to 20.9 months, compared with 16.0 months only in the temozolomide-alone group (HR, 0.63; 95% CI, 0.53-0.76; P < .001).

TTFields are a novel treatment modality for the treatment of malignant tumors that is also referred to as the fourth modality of cancer treatment in addition to surgery, radiation therapy, and chemotherapy. Pre-clinical studies3-9 have shown this treatment modality to effectively inhibit the growth of experimental tumors both in-vitro and in-vivo without any systemic side effects. Large-scale, phase III clinical studies have validated the safety and efficacy of TTFields in patients with recurrent and newly diagnosed glioblastoma10,11. TTFields has now been approved as a standard treatment for GBM by most of the regulatory agencies around the world and its application is steadily increasing worldwide.

Standard Treatment of GBM

The currently accepted standard treatment of newly diagnosed GBM is based on: surgical resection to the extent safely feasible followed by RT with concomitant TMZ, followed by adjuvant TMZ chemotherapy in combination with TTFields. Each of these treatments is briefly described below:

  1. Surgical resection - Treatment of patients with GBM usually consists of tumor resection (to the extent safely feasible) or diagnostic biopsy.
  2. Radiotherapy (RT) - Post-surgical RT improves survival, though even with maximal treatment, survival after RT alone is still limited to about one year1.
  3. Temozolomide (TMZ) - Concomitant TMZ chemotherapy during RT and adjuvant (maintenance) TMZ for 6 cycles has been shown to significantly improve survival (HR 0.63). This combined modality treatment is considered the standard of care.
  4. According to the TMZ (Temodar, Temodal) package insert adjuvant TMZ treatment delays disease progression (from 5 to 6.9 months) and improves overall survival (from 12.1 to 14.6 months)1.
  5. In the RTOG0525/EORTC Intergroup trial where patients were randomized after the end of TMZ/RT (similar to the EF-14 trial), progression-free survival was also only 6-7 months (estimated from curve)12
  6. GLIADEL Wafers in combination with surgical resection - Gliadel Wafers deliver carmustine (BCNU) directly to the bed of the resected tumor. Gliadel has been approved for GBM after surgical resection, based on trials performed before TMZ therapy was established13.
  7. The package insert indicates that for newly diagnosed GBM, Gliadel increased median overall survival from 11.6 to 13.9 months compared to placebo. Progression-free survival with Gliadel wafers has been reported as 5.9 months27. No prospective data of Gliadel in combination with TMZ has been reported.
  8. TTFields - Clinical trials of TTFields have proven safe and efficacious in patients with recurrent and newly diagnosed GBM. The median OS in the large scale phase III clinical study in newly diagnosed GBM patients (EF-14) was 20.9 months in the TTFields plus TMZ group vs. 16 months in the TMZ alone group11. Accordingly, TTFields (Optune) are now FDA-approved for use in newly diagnosed and recurrent GBM.

In conclusion, despite the improvement in OS following the introduction of TTFields into the standard of care for newly diagnosed GBM patients, the survival of most patients remains poor. Therefore, new treatments, as well as strategies for maximizing the benefit from currently available therapies are needed.

STUDY DESIGN A prospective, randomly controlled pivotal study will be conducted on 60 patients (randomized at a 1:1 ratio). Patients with histologically confirmed GBM will be randomized after debulking surgery or biopsy to either RT with concomitant TMZ and TTFields (200 kHz) for 6 weeks followed by up to 24 months of maintenance TMZ in combination with TTFields (experimental arm), or RT with concomitant TMZ alone followed by maintenance TMZ chemotherapy in combination with TTFields (control). The primary endpoint will be rate of progression free survival at 12 months (PFS12). The sample size was chosen based on the Exact test for proportion (See XX Statistical Considerations). In short, in order to detect a PFS12 of 46.5% in patients treated with RT/TMZ/TTFields followed by maintenance TMZ+TTFields, compared to the 29.4% calculated from the EF-14 experimental arm of patients treated with RT/TMZ alone followed by maintenance TMZ+TTFields, a sample size of 60 patients randomized in a ratio of 1:1 (30 patients in each arm) is required to achieve a power of 80% at two-sided alpha level of 0.05 using the Exact test for proportion.

The following will be considered disease progression (based on the RANO criteria; Tab D):

  1. 25% or more increase in enhancing lesions despite stable or increasing steroid dose
  2. Increase (significant) in non-enhancing FLAIR/T2W lesions, not attributable to other non-tumor causes
  3. Any new lesions Progression suspected from a clinical evaluation of the patient will need to be radiologically confirmed using an MRI scan. The criteria will not be applied in case of suspected pseudoprogression, unless the tumor continues to grow.

Condition Glioblastoma Multiforme, glioblastoma
Treatment NovoTTF-200A
Clinical Study IdentifierNCT03869242
SponsorTel-Aviv Sourasky Medical Center
Last Modified on22 January 2021


Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have any of these conditions: glioblastoma or Glioblastoma Multiforme?
Histologically confirmed diagnosis of GBM according to WHO classification criteria
age 18 years
Recovered from debulking surgery or biopsy-only
Planned treatment with RT/TMZ following maintenance TMZ (150-200 mg/m2 daily x 5 d, q28 days)
Karnofsky performance status 70%
Life expectancy least 3 months
Participants of childbearing age must use effective contraception
All patients must sign written informed consent
Stable or decreasing dose of corticosteroids for the last 7 days prior to randomization, if applicable

Exclusion Criteria

Early progressive disease before initiation of TMZ/RT
Participation in another clinical treatment trial
Significant co-morbidities at baseline which would preclude maintenance RT or TMZ treatment, as determined by the investigator
Thrombocytopenia (platelet count < 100 x 103/L)
Neutropenia (absolute neutrophil count < 1.5 x 103/L)
CTC grade 4 non-hematological Toxicity (except for alopecia, nausea, vomiting)
Significant liver function impairment - AST or ALT > 3 times the upper limit of normal
Total bilirubin > 1.5 x upper limit of normal
Significant renal impairment (serum creatinine > 1.7 mg/dL, or > 150 mol/l)
Implanted pacemaker, defibrillator, deep brain stimulator, other implanted electronic devices in the brain, or documented clinically significant arrhythmias
Evidence of increased intracranial pressure (midline shift > 5mm, clinically significant papilledema, vomiting and nausea or reduced level of consciousness)
History of hypersensitivity reaction to TMZ or a history of hypersensitivity to DTIC
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note